{"id":"avelumab-weekly","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-mediated pneumonitis"},{"rate":null,"effect":"Immune-mediated hepatitis"},{"rate":null,"effect":"Immune-mediated colitis"},{"rate":null,"effect":"Hypothyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Avelumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the PD-L1/PD-1 and PD-L1/B7.1 inhibitory pathways. This releases the brake on T-cell activation, allowing the immune system to recognize and attack cancer cells more effectively. The weekly dosing schedule is designed to optimize convenience and potentially improve patient compliance compared to standard dosing intervals.","oneSentence":"Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:10.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic Merkel cell carcinoma"},{"name":"Urothelial carcinoma (bladder cancer)"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04004442","phase":"PHASE1","title":"Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oklahoma","startDate":"2020-02-17","conditions":"Urothelial Carcinoma","enrollment":19},{"nctId":"NCT06302426","phase":"PHASE1","title":"Trial of INI-4001 in Patients With Advanced Solid Tumours","status":"RECRUITING","sponsor":"Inimmune Corporation","startDate":"2024-07-01","conditions":"Advanced Solid Tumor","enrollment":50},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04266912","phase":"PHASE1, PHASE2","title":"Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-17","conditions":"Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":23},{"nctId":"NCT03826589","phase":"NA","title":"Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-06-01","conditions":"Cervical Cancer","enrollment":23},{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03724890","phase":"PHASE1","title":"Study of Avelumab-M3814 Combinations","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2018-11-27","conditions":"Oncology, Solid Tumors","enrollment":57},{"nctId":"NCT03498378","phase":"PHASE1","title":"Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kathryn Gold","startDate":"2018-06-06","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT03747484","phase":"PHASE1, PHASE2","title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-03","conditions":"Other Skin","enrollment":7},{"nctId":"NCT03636503","phase":"PHASE1","title":"Rituximab + Immunotherapy in Follicular Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-30","conditions":"Follicular Lymphoma","enrollment":24},{"nctId":"NCT02576574","phase":"PHASE3","title":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-10-29","conditions":"First Line Non-Small Cell Lung Cancer","enrollment":1214},{"nctId":"NCT06640725","phase":"PHASE2","title":"Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N","status":"RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2025-01-02","conditions":"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","enrollment":70},{"nctId":"NCT02994953","phase":"PHASE1","title":"A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2017-01-31","conditions":"Advanced Solid Tumors","enrollment":52},{"nctId":"NCT03490292","phase":"PHASE1, PHASE2","title":"Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-05-29","conditions":"Resectable Esophageal Cancer, GastroEsophageal Cancer","enrollment":22},{"nctId":"NCT03523390","phase":"PHASE1","title":"Phase I/Ib Multiple Ascending Dose Study in China","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-04-24","conditions":"Metastatic Solid Tumors","enrollment":24},{"nctId":"NCT03892642","phase":"PHASE1, PHASE2","title":"Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2019-05-01","conditions":"Bladder Cancer","enrollment":18},{"nctId":"NCT05291156","phase":"PHASE2","title":"CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2022-07-21","conditions":"Metastatic Colorectal Cancer","enrollment":173},{"nctId":"NCT05249569","phase":"PHASE2","title":"Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-04","conditions":"Hepatocellular Carcinoma","enrollment":1},{"nctId":"NCT03827044","phase":"PHASE3","title":"Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2018-08-31","conditions":"POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer","enrollment":30},{"nctId":"NCT04561336","phase":"PHASE2","title":"Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-08-10","conditions":"Metastatic Colorectal Cancer, RAS Wild Type","enrollment":77},{"nctId":"NCT03268057","phase":"PHASE1, PHASE2","title":"VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Vaccinex Inc.","startDate":"2017-10-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":62},{"nctId":"NCT01772004","phase":"PHASE1","title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2013-01-31","conditions":"Solid Tumors","enrollment":1756},{"nctId":"NCT03158883","phase":"EARLY_PHASE1","title":"UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients","status":"COMPLETED","sponsor":"Megan Daly, MD","startDate":"2017-05-17","conditions":"Metastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT03451773","phase":"PHASE1, PHASE2","title":"M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-17","conditions":"Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma","enrollment":7},{"nctId":"NCT02718417","phase":"PHASE3","title":"Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-05-19","conditions":"Ovarian Cancer","enrollment":998},{"nctId":"NCT02938273","phase":"PHASE1","title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-01","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anti-PD-L1","MSB0010718C"],"phase":"phase_3","status":"active","brandName":"Avelumab Weekly","genericName":"Avelumab Weekly","companyName":"EMD Serono Research & Development Institute, Inc.","companyId":"emd-serono-research-development-institute-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses. Used for Metastatic Merkel cell carcinoma, Urothelial carcinoma (bladder cancer), Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}